Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors

ABSTRACT Antivector immunity may limit the immunogenicity of adenovirus vector vaccines. We tested sera from individuals immunized with adenovirus type 4 and 7 (Ad4 and Ad7, respectively) vaccine or naturally infected with Ad4 for their ability to neutralize a panel of E1-deleted human and chimpanzee adenoviruses (ChAd). Small statistically significant increases in titers to ChAd63, ChAd3, human Ad35, and human Ad5 were observed. Neutralizing antibodies elicited by Ad4 infection or immunization results in a small amount of adenovirus cross-reactivity.

[1]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[2]  Kylie M. Quinn,et al.  Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization , 2013, The Journal of Immunology.

[3]  A. Folgori,et al.  Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector , 2012, The Journal of infectious diseases.

[4]  A. Folgori,et al.  Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species , 2012, Science Translational Medicine.

[5]  A. Folgori,et al.  Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.

[6]  Jerome H. Kim,et al.  Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 , 2010, Expert review of vaccines.

[7]  N. Wolfe,et al.  International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. , 2010, Vaccine.

[8]  S. McCormack,et al.  Faculty Opinions recommendation of Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. , 2009 .

[9]  A. Nicosia,et al.  Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. , 2009, Vaccine.

[10]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[11]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[12]  D. Metzgar,et al.  A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. , 2008, Vaccine.

[13]  J. Kublin,et al.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N. Letvin,et al.  Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.

[15]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[16]  A. Heim,et al.  Phylogenetic Analysis of the Main Neutralization and Hemagglutination Determinants of All Human Adenovirus Prototypes as a Basis for Molecular Classification and Taxonomy , 2005, Journal of Virology.

[17]  G. Nabel,et al.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1. , 2005, Human gene therapy.

[18]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[19]  Jaap Goudsmit,et al.  Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.

[20]  D. Vaughn,et al.  Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  G. Gray,et al.  Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. army trainees. , 1999, Emerging infectious diseases.

[22]  J. Gaydos,et al.  Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination. , 1999, The Journal of infectious diseases.

[23]  J. Gall,et al.  Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype , 1998, Journal of Virology.

[24]  R. Wigand.  Pitfalls in the identification of adenoviruses. , 1987, Journal of virological methods.

[25]  C. G. Loosli,et al.  Neutralizing and complement fixing antibody response to adenovirus infection. , 1956, The Journal of infectious diseases.

[26]  John O. Konz,et al.  Production and formulation of adenovirus vectors. , 2005, Advances in biochemical engineering/biotechnology.

[27]  G. Beeson,et al.  in adults with , 2019 .